Zymergen’s problems were evident to board shortly after IPO, SEC filings show


The filings come in advance of a merger with a rival for $300 million — a small fraction of the billions Zymergen once hoped to generate.

Previous Drew Tyrer named CEO of TriStar Southern Hills Medical Center
Next Milkman burger restaurant opens in OTR in former Revolution Rotisserie space